Directors


Prof. dr. Jan Paul Medema

Scientific director of Cancer Center Amsterdam and professor in Experimental oncology and radiobiology. As scientific director of CCA I represent all research within our Cancer Center, but my own research team is studying the heterogeneity of colorectal cancer from a biological and clinical perspective. Molecular classification of colorectal cancer is at the basis of our research in which we aim to understand the underlying biology of subtypes, their origin and above all try to devise novel therapeutic avenues. Scientific director of Cancer Center Amsterdam and professor in Experimental oncology and radiobiology. As scientific director of CCA I represent all research within our Cancer Center, but my own research team is studying the heterogeneity of colorectal cancer from a biological and clinical perspective. Molecular classification of colorectal cancer is at the basis of our research in which we aim to understand the underlying biology of subtypes, their origin and above all try to devise novel therapeutic avenues.

Research board members


Prof. dr. Geert Kazemier

Geert Kazemier was appointed professor of hepatobiliary surgery and transplantation at Amsterdam UMC, location VUmc, in January 2012 and is currently responsible for surgical oncology and abdominal surgery at that institution.  He is (clinical) director of Cancer Center Amsterdam and director of both Cancer Center Amsterdam and ADORE Foundations at Amsterdam UMC, location VUmc Geert Kazemier was appointed professor of hepatobiliary surgery and transplantation at Amsterdam UMC, location VUmc, in January 2012 and is currently responsible for surgical oncology and abdominal surgery at that institution. He is (clinical) director of Cancer Center Amsterdam and director of both Cancer Center Amsterdam and ADORE Foundations at Amsterdam UMC, location VUmc

Prof. dr. Louis Vermeulen

Fellow in medical oncology and PI experimental oncology. The focus of my multidisciplinary research team is colorectal cancer. We study stem cell dynamics in developing and established cancers to improve prevention and therapy. Simultaneously we aim to drive molecular classification of the disease into clinical practice. I represent the Cancer Biology theme which is the backbone of fundamental and translational research at the CCA. Fellow in medical oncology and PI experimental oncology. The focus of my multidisciplinary research team is colorectal cancer. We study stem cell dynamics in developing and established cancers to improve prevention and therapy. Simultaneously we aim to drive molecular classification of the disease into clinical practice. I represent the Cancer Biology theme which is the backbone of fundamental and translational research at the CCA.

Prof. dr. Marjolein van Egmond

Professor in oncology and inflammation. The translational research of my group addresses immunotherapy of cancer, with the emphasis on colorectal cancer.  We investigate the activation of myeloid effector cells by next generation engineered antibodies, and their ability to directly eliminate cancer cells as well as the capacity to induce anti-tumour adaptive immune responses.  We develop novel antibody-based therapies to target cancer with special attention to the peri-operative setting.  I represent the Cancer Immunology theme. Professor in oncology and inflammation. The translational research of my group addresses immunotherapy of cancer, with the emphasis on colorectal cancer. We investigate the activation of myeloid effector cells by next generation engineered antibodies, and their ability to directly eliminate cancer cells as well as the capacity to induce anti-tumour adaptive immune responses. We develop novel antibody-based therapies to target cancer with special attention to the peri-operative setting. I represent the Cancer Immunology theme.

Dr. Marcel Spaargaren

Leader of the CCA theme Target & Therapy Discovery and PI at the department of Pathology. The focus of my research team is on hemato-oncology, in particular the molecular and cellular aspects of the pathogenesis of mature B-cell malignancies (lymphoma, leukemia and multiple myeloma). We aim to identify oncogenic signaling pathways and to explore and exploit microenvironment-dependence as the Achilles’ heel of these B-cell malignancies. I represent the T & TD theme, which is all about identification of novel targets and drugs and their translation into clinical applications Leader of the CCA theme Target & Therapy Discovery and PI at the department of Pathology. The focus of my research team is on hemato-oncology, in particular the molecular and cellular aspects of the pathogenesis of mature B-cell malignancies (lymphoma, leukemia and multiple myeloma). We aim to identify oncogenic signaling pathways and to explore and exploit microenvironment-dependence as the Achilles’ heel of these B-cell malignancies. I represent the T & TD theme, which is all about identification of novel targets and drugs and their translation into clinical applications

Prof. dr. Ronald Boellaard

Full professor in medical physics and PET imaging methodology. The focus of my research team is medical imaging methodology and image quantification. We develop and translate new PET pharmacokinetic models and methods for new radiotracers, image processing and analysis methods, radiomics and artificial intelligence and put effort in the clinical validation of new quantitative imaging biomarkers. I represent the Imaging theme which represents the fundamental, translational and (pre-)clinical imaging research at the CCA. Full professor in medical physics and PET imaging methodology. The focus of my research team is medical imaging methodology and image quantification. We develop and translate new PET pharmacokinetic models and methods for new radiotracers, image processing and analysis methods, radiomics and artificial intelligence and put effort in the clinical validation of new quantitative imaging biomarkers. I represent the Imaging theme which represents the fundamental, translational and (pre-)clinical imaging research at the CCA.

Dr. D.Michiel Pegtel

PI in experimental pathology, head of the exosomes research group. We investigate how cancer cells exploit  small vesicles (exosomes) to communicate in the tumor environment and study the effects on tumor growth and response to therapy. We aim to develop practical methods for non-invasive cancer diagnosis and drug delivery.  I represent the Cancer Biomarker Theme and support researchers with valorization i.e. translating laboratory discoveries into real benefit for our patients. PI in experimental pathology, head of the exosomes research group. We investigate how cancer cells exploit small vesicles (exosomes) to communicate in the tumor environment and study the effects on tumor growth and response to therapy. We aim to develop practical methods for non-invasive cancer diagnosis and drug delivery. I represent the Cancer Biomarker Theme and support researchers with valorization i.e. translating laboratory discoveries into real benefit for our patients.

Prof. dr. Marc G.H. Besselink

Professor of surgery, specializing in pancreatic and hepato-biliary surgery. The focus of our multidisciplinary research team is pancreatic and periampullary cancer and minimally invasive surgery. The research is integrated in large nationwide and international cohorts and randomized trials including the Dutch Pancreatic Cancer Audit, Dutch Pancreas Biobank, Dutch Pancreatic Cancer Group and the European and International Consortium on Minimally Invasive Pancreatic Surgery. I represent the Cancer Therapy theme which represents a large group of clinicians performing cancer related research at the CCA. Professor of surgery, specializing in pancreatic and hepato-biliary surgery. The focus of our multidisciplinary research team is pancreatic and periampullary cancer and minimally invasive surgery. The research is integrated in large nationwide and international cohorts and randomized trials including the Dutch Pancreatic Cancer Audit, Dutch Pancreas Biobank, Dutch Pancreatic Cancer Group and the European and International Consortium on Minimally Invasive Pancreatic Surgery. I represent the Cancer Therapy theme which represents a large group of clinicians performing cancer related research at the CCA.

Dr. Martijn G.H. van Oijen

Clinical epidemiologist and PI medical oncology. The focus of my research team is evaluation of quality of cancer care. We study the feasibility and efficacy of patient monitoring systems using patient-reported outcomes augmented with wearable activity trackers. Simultaneously, we aim to develop and evaluate prediction models based on large clinical data sets, such as PALGA and the National Cancer Registry, using state-of-the art information technology. I am the co-chair of the Therapy theme, which is the largest clinical research theme at the CCA. Clinical epidemiologist and PI medical oncology. The focus of my research team is evaluation of quality of cancer care. We study the feasibility and efficacy of patient monitoring systems using patient-reported outcomes augmented with wearable activity trackers. Simultaneously, we aim to develop and evaluate prediction models based on large clinical data sets, such as PALGA and the National Cancer Registry, using state-of-the art information technology. I am the co-chair of the Therapy theme, which is the largest clinical research theme at the CCA.

Prof. dr. Lia van Zuylen

Medical oncologist and professor of clinical palliative care. I represent the Supportive Care theme. This theme aims to prevent or treat symptoms, and physical, psychosocial, and spiritual problems related to cancer and cancer treatment. Research in this theme focuses on the development, evaluation and implementation of supportive care programs for patients with cancer to optimize the patient’s quality of life in every phase of the disease. This involves a broad range of research from optimizing cancer treatment tolerability to the best care in the last phase of life. Medical oncologist and professor of clinical palliative care. I represent the Supportive Care theme. This theme aims to prevent or treat symptoms, and physical, psychosocial, and spiritual problems related to cancer and cancer treatment. Research in this theme focuses on the development, evaluation and implementation of supportive care programs for patients with cancer to optimize the patient’s quality of life in every phase of the disease. This involves a broad range of research from optimizing cancer treatment tolerability to the best care in the last phase of life.